Navigating health choices during midlife and menopause often involves considering supplements alongside prescribed medications. Rhodiola rosea is a botanical often explored for its potential adaptogenic properties. Like many botanicals, though, it can change how the body handles other drugs, and that is one of the more concrete safety questions with this herb.
This article walks through the actual data: what laboratory studies found, what the one human trial measured, where animal studies disagree, and what that means for antidepressants and other medications. It is information to bring to your prescriber, not a substitute for them.
Key Takeaways
- In a randomised cross-over trial of 13 healthy volunteers, 14 days of a commercial Rhodiola rosea product cut CYP2C9 activity by a statistically significant 21%. CYP1A2, CYP2C19, CYP2D6 and CYP3A4 showed no significant change.
- Laboratory (in vitro) studies found rhodiola compounds and extracts inhibit CYP2D6, CYP3A4 and P-glycoprotein. In people, only the CYP2C9 effect has been measured.
- The authors of the human trial flagged narrow-margin CYP2C9 drugs such as warfarin and phenytoin as the ones where the effect could matter.
- Commercial products differ widely in how strongly they inhibit these enzymes, and the amount of marker compounds on the label did not predict it.
- Isolated salidroside looks cleaner in preclinical testing, but that does not automatically apply to whole-root extracts.
Understanding Drug Metabolism and Rhodiola Rosea
Many medications are processed by a family of liver enzymes called cytochrome P450 (CYP) enzymes. If a substance slows one of these enzymes, drugs that depend on it can build up to higher levels than the prescriber planned for. Whether Rhodiola rosea does this has been tested in the lab, in animals and, once, in people.
The human data comes from a randomised cross-over trial in which 13 healthy volunteers took single doses of a cocktail of test drugs, with and without 14 days of pretreatment with a commercial Rhodiola rosea product. The test drugs were caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6) and midazolam (CYP3A4). The ratio of EXP-3174 (the metabolite CYP2C9 makes from losartan) to losartan fell by a statistically significant 21% (p = 0.023), indicating reduced CYP2C9 activity. The effect was more pronounced in CYP2C9 extensive metabolizers than in intermediate and poor metabolizers [1].
The authors called the effect modest but said it might be clinically relevant during treatment with CYP2C9 substrates that have a narrow therapeutic index, naming phenytoin and warfarin [1]. A follow-up laboratory study on the same commercial product found it inhibits human CYP2C9 noncompetitively, which fits the human result [2].
What Laboratory Studies Add: CYP2D6, CYP3A4 and P-glycoprotein
Two further findings come from test-tube work only. Using human liver microsomes, the rhodiola compounds rhodiosin and rhodionin inhibited CYP2D6 non-competitively, with IC50 values of 0.761 µM and 0.420 µM, while the other six main components tested showed no obvious inhibition [3]. CYP2D6 handles a wide range of drugs, including many antidepressants, so this is the finding people usually worry about.
Separately, extracts of six Rhodiola rosea clones from different parts of Norway all inhibited CYP3A4-mediated metabolism and P-glycoprotein efflux transport, with IC50 values below those reported for St. John’s wort and fluoxetine, two substances known for herb-drug and drug-drug interactions. The authors concluded rhodiola might be a candidate for clinically relevant interactions [4].
What the Human Trial Did Not Find
The same 13-person trial is the best evidence against the broadest reading of the lab data. After 14 days of the rhodiola product, the markers for CYP1A2, CYP2C19, CYP2D6 and CYP3A4 showed no significant effect [1]. In other words, the CYP2D6 and CYP3A4 inhibition seen in the lab was not measured in people in that trial.
That gap is common with herbs. Enzyme assays expose the enzyme directly to extract concentrations that may never reach the liver after an oral capsule, so a potent test-tube result is a reason to look, not proof of an effect in people. One trial of 13 healthy volunteers using one product for two weeks also cannot rule out an effect at higher doses, over longer use, or in people taking several interacting drugs at once.
Not Every Product Behaves the Same
A comparison of six commercial rhodiola products found large differences in how strongly they inhibited CYP enzymes in vitro, with IC50 values ranging from 7.2 to 106.6 µg/mL for CYP3A4 and from 13.0 to 186.1 µg/mL for CYP2D6. A tincture was the strongest inhibitor of all three enzymes tested, one of the six products contained none of the rosavin, rosarin or rosin that mark Rhodiola rosea, and constituent concentrations were not linked to enzyme inhibition [5]. A rosavin percentage on the label therefore tells you about standardization, not about interaction risk.
Animal Studies Point in Both Directions
In six rabbits given losartan together with a rhodiola herbal product, losartan’s peak level and total exposure (AUC) rose significantly, with an almost 2-fold increase in AUC, while the active metabolite EXP3174 did not change significantly. The authors called for a human study [6].
A rat study of the SHR-5 extract found the opposite: given alongside warfarin it did not significantly alter warfarin’s pharmacokinetics or anticoagulant activity, and theophylline was also unaffected [7]. That study came from the Swedish Herbal Institute, which makes the extract, and it was done in rats, so it is reassuring at most, not a clearance to combine rhodiola with warfarin.
Rhodiola Rosea and Antidepressants
Antidepressants are a major concern for many people, particularly women navigating midlife and menopause who may be considering both. Antidepressants work by affecting neurotransmitter levels in the brain, and CYP2D6 is one of the enzymes that clears many of them.
Direct, robust human studies of rhodiola with specific antidepressants are lacking. What exists is indirect: the CYP2D6 inhibition seen in the lab [3], balanced by the human trial in which a CYP2D6 marker did not change [1]. A Polish analysis of 147 cases of suspected herb-drug adverse events, mostly involving psychotropic drugs, listed rhodiola rosea among the herbs associated with a significant risk of pharmacokinetic and pharmacodynamic interactions with psychotropic medication. In that series the specific complications reported for antidepressants were mostly tied to other herbs, such as ginkgo and ginseng, while rhodiola appeared in the antipsychotic group [8].

For a closer look at specific antidepressant classes, see our guide to rhodiola and antidepressants. The practical point is the same either way: ask your prescriber or pharmacist before combining rhodiola with any antidepressant, since an interaction could alter the drug’s effect or raise the risk of side effects.
Isolated Salidroside Looks Cleaner, but It Is Not the Whole Root
Salidroside is a key active compound in Rhodiola rosea. A laboratory study found that bioengineered salidroside, at concentrations above the predicted plasma level of under 2 µM (based on a 60 mg oral dose), showed no risk of drug interaction through CYP enzymes, MAO enzymes or OATP transporters. Its authors are linked to the company that commercializes that salidroside [9]. A 2026 preclinical study in rats and human liver microsomes, with no company link declared, likewise found that salidroside did not directly inhibit the P450 enzymes studied and concluded it is unlikely to pose a significant risk of P450-mediated herb-drug interactions [10].
Those results apply to the isolated compound. Whole-root extracts also contain rhodiosin, rhodionin and other constituents implicated in the inhibition findings above, so the salidroside data should not be read as clearing a rhodiola capsule.
Other Potential Drug Interactions
Medications that affect blood pressure, blood clotting or blood sugar are often considered in the context of botanical interactions, but conclusive evidence for rhodiola in combination with these drugs is still developing. The CYP2C9 finding is the most concrete lead, because several narrow-margin drugs depend on that enzyme. See our guide to rhodiola and blood pressure medications for that topic. Keep a short list of everything you take, including any supplement products, and share it with your pharmacist.
Navigating Supplement and Medication Use During Midlife and Menopause
Midlife and menopause often bring new health considerations and, for many women, new medications or supplements. A proactive approach to understanding what you are taking is essential, and many women explore botanicals like Rhodiola rosea for support during this time.
The practical takeaway is narrower than a blanket warning. If you take a CYP2C9 substrate with a narrow therapeutic index, such as warfarin or phenytoin, raise rhodiola with your prescriber before you start it, not after [1]. If you and your prescriber decide it is reasonable, sticking to one product and mentioning it whenever you start, stop or switch makes any change easier to spot, since products vary in how strongly they inhibit these enzymes [5].
Importance of Professional Guidance
Because the evidence is partly lab-based, partly animal and only partly human, professional guidance is invaluable. Your healthcare provider can assess your individual health profile, current medications and specific concerns, and help you weigh the potential benefits and risks of adding Rhodiola rosea to your regimen.

When discussing rhodiola with your healthcare provider, give a complete list of all prescription medications, over-the-counter drugs, other supplements and herbal products you are taking. This allows the most informed assessment of potential interactions.
Frequently Asked Questions
Does Rhodiola rosea interact with medications?
It can. A human trial found a modest but statistically significant reduction in CYP2C9 activity after 14 days of a commercial product, and laboratory studies show inhibition of CYP2D6, CYP3A4 and P-glycoprotein that has not been confirmed in people.
Is Rhodiola rosea safe to take with blood thinners like warfarin?
Warfarin is metabolized partly by CYP2C9, which the human trial found rhodiola inhibits, and the trial authors named warfarin as a drug where the effect may matter. A rat study of one extract found no change in warfarin pharmacokinetics. Anyone on warfarin should talk to a physician or pharmacist before combining it with rhodiola.
Is isolated salidroside as risky as whole rhodiola extract for interactions?
Preclinical testing suggests isolated salidroside has a cleaner interaction profile, but the inhibition data above comes from whole-extract and specific-compound (rhodiosin and rhodionin) studies, so it should not be assumed to apply identically to every rhodiola product.
References
- Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. European journal of clinical pharmacology, 2016
- Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product. Pharmacology research & perspectives, 2017
- Two potent cytochrome P450 2D6 inhibitors found in Rhodiola rosea. Pharmazie, 2013
- Potent in vitro inhibition of CYP3A4 and P-glycoprotein by Rhodiola rosea. Planta medica, 2010
- In vitro inhibition of cytochrome P-450 activities and quantification of constituents in a selection of commercial Rhodiola rosea products. Pharmaceutical biology, 2016
- Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits. Pharmacology, 2013
- Pharmacokinetic and pharmacodynamic study of interaction of Rhodiola rosea SHR-5 extract with warfarin and theophylline in rats. Phytotherapy research, 2009
- Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts. Psychiatria polska, 2018
- In Vitro Evaluation of the Potential for Drug Interactions by Salidroside. Nutrients, 2023
- The effect of salidroside, an active component of Rhodiola rosea, on the metabolic activity of rat and human cytochromes P450 in preclinical studies. Pharmacological reports, 2026
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.